Veru Inc. (VERU) Stock Price

VERUStock

$2.30−44.84%52W

Market Cap$39.22M

P/E—

PEG Ratio3.60

Div yield—

Beta-1.20

VERU Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-14.86%

Price vs S&P 500 (4W)-4.41%

PEG Ratio3.60

VGM Score60.65

Book Value / Share (Quarterly)$1.66

P/TBV (Annual)3.48x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-34.92%

Cash Flow / Share (Quarterly)$-1.53

Price vs S&P 500 (YTD)-4.45%

Gross Margin (TTM)34.66%

Net Profit Margin (TTM)-223.86%

EPS (TTM)$-0.59

10-Day Avg Trading Volume0.34M

EPS Excl Extra (TTM)$-0.59

Revenue Growth (5Y)-11.89%

EPS (Annual)$-2.80

ROI (Annual)-89.59%

Gross Margin (Annual)34.67%

Net Profit Margin (5Y Avg)-208.17%

Cash / Share (Quarterly)$1.51

Revenue Growth QoQ (YoY)72.36%

ROA (Last FY)-62.57%

Revenue Growth TTM (YoY)3.62%

EBITD / Share (TTM)$-0.94

ROE (5Y Avg)-150.44%

Operating Margin (TTM)-218.61%

Cash Flow / Share (Annual)$-2.05

P/B Ratio1.38x

P/B Ratio (Quarterly)1.77x

Net Income / Employee (Annual)$-1,890,100

EV / Revenue (TTM)0.91x

Net Interest Coverage (TTM)-42.80x

ROA (TTM)-34.56%

EV / EBITDA (TTM)1.16x

EPS Incl Extra (Annual)$-2.80

Current Ratio (Annual)2.43x

Quick Ratio (Quarterly)4.19x

3-Month Avg Trading Volume0.29M

52-Week Price Return-44.84%

Revenue / Employee (TTM)$844,300

Tangible BV / Share (Quarterly)$2.21

P/S Ratio (Annual)2.32x

Asset Turnover (Annual)0.28x

52-Week High$7.33

Operating Margin (5Y Avg)-203.80%

EPS Excl Extra (Annual)$-2.80

CapEx CAGR (5Y)-60.34%

Tangible BV CAGR (5Y)21.71%

26-Week Price Return-4.96%

Quick Ratio (Annual)2.35x

13-Week Price Return-3.36%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.42x

Enterprise Value$15.34M

Revenue / Share Growth (5Y)20.05%

Asset Turnover (TTM)0.24x

Book Value / Share Growth (5Y)23.78%

Revenue / Employee (Annual)$844,300

Inventory Turnover (Annual)2.04x

Pretax Margin (Annual)-219.56%

Cash / Share (Annual)$1.25

3-Month Return Std Dev64.93%

Gross Margin (5Y Avg)61.87%

Net Income / Employee (TTM)$-680,400

ROE (Last FY)-116.97%

Net Interest Coverage (Annual)-42.83x

EPS Basic Excl Extra (Annual)$-2.80

P/FCF (TTM)9.87x

Receivables Turnover (TTM)3.99x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.59

Receivables Turnover (Annual)3.99x

ROI (TTM)-45.89%

P/S Ratio (TTM)2.32x

Pretax Margin (5Y Avg)-208.12%

Revenue / Share (Annual)$1.25

Tangible BV / Share (Annual)$2.21

Price vs S&P 500 (52W)-60.38%

Year-to-Date Return7.48%

5-Day Price Return-4.37%

EPS Normalized (Annual)$-2.80

ROA (5Y Avg)-68.61%

Net Profit Margin (Annual)-223.86%

Month-to-Date Return-13.53%

Cash Flow / Share (TTM)$-1.49

EBITD / Share (Annual)$-2.72

Operating Margin (Annual)-218.61%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-107.33%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.59

P/TBV (Quarterly)3.48x

P/B Ratio (Annual)3.04x

Inventory Turnover (TTM)2.04x

Pretax Margin (TTM)-219.56%

Book Value / Share (Annual)$1.25

Price vs S&P 500 (13W)-6.05%

Beta-1.20x

P/FCF (Annual)46.14x

Revenue / Share (TTM)$1.15

ROE (TTM)-45.89%

52-Week Low$2.05

vGradeB

gGradeC

mGradeC

vgmGradeB

VERU Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	-$0.32	-$0.30	+6.25%(+$0.02)
Q1 2026	May 13, 2026	-$0.28	-$0.13	+54.39%(+$0.15)
Q4 2025	Feb 11, 2026	-$0.47	-$0.26	+44.68%(+$0.21)
Q3 2025	Dec 17, 2025	-$0.39	$0.09	+123.08%(+$0.48)
Q2 2025	Aug 12, 2025	-$0.50	-$0.53	-6.53%(-$0.03)

VERU Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.25

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
VERUVeru Inc.	B	C	C	2.3x	3.6%	34.7%	—	$2.30
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Veru Inc.

Veru is a late-stage biopharmaceutical developing therapies for cardiometabolic and inflammatory diseases. Enobosarm, a selective androgen receptor modulator, is in Phase 2b development for obesity to enhance fat loss selectivity when combined with GLP-1 RA drugs. Sabizabulin, an oral microtubule disruptor, is advancing to Phase 2 trials for atherosclerotic cardiovascular disease to reduce inflammation and high-sensitivity CRP levels.

VERU Insider Transactions

BuyAug 13, 2026
BARNETTE K GARY PH.D.
Officer
Shares: 1,800Value: $4,842

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

VGASVerde Clean Fuels, Inc. Class A Common StockIndustrial Chemicals
INMBINmune Bio Inc. Common stockBiological Products
BYAHPark Ha Biological Technology Co., Ltd. Ordinary SharesSoap & Detergents
TILInstil Bio, Inc. Common StockBiological Products
BSEMBioStem Technologies, Inc. Common StockBiological Products
EXOZeXoZymes Inc. Common StockBiological Products
AXILAXIL Brands, Inc.Cosmetics & Toiletries
BTMDBiote Corp. Class A Common StockPharmaceutical Preparations

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$2.05

High$7.33